Generate Biomedicines, Inc. (NASDAQ: GENB) Stock Competitors & Peer Comparison

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, VRTX has a market cap of 129B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while VRTX trades at $508.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas VRTX's P/E ratio is 26.70. In terms of profitability, GENB's ROE is -0.27%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, GENB is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for GENB.Check VRTX's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, REGN has a market cap of 80.9B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while REGN trades at $784.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas REGN's P/E ratio is 17.20. In terms of profitability, GENB's ROE is -0.27%, compared to REGN's ROE of +0.14%. Regarding short-term risk, GENB is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for GENB.Check REGN's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas VRNA's P/E ratio is -102.80. In terms of profitability, GENB's ROE is -0.27%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, GENB is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for GENB.Check VRNA's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, ARGX has a market cap of 61.6B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while ARGX trades at $990.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas ARGX's P/E ratio is 89.38. In terms of profitability, GENB's ROE is -0.27%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, GENB is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for GENB.Check ARGX's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, MRNA has a market cap of 61.1B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while MRNA trades at $154.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas MRNA's P/E ratio is -18.90. In terms of profitability, GENB's ROE is -0.27%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, GENB is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for GENB.Check MRNA's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas SGEN's P/E ratio is -57.19. In terms of profitability, GENB's ROE is -0.27%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, GENB is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for GENB.Check SGEN's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, RVMD has a market cap of 40.6B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while RVMD trades at $190.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas RVMD's P/E ratio is -21.64. In terms of profitability, GENB's ROE is -0.27%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, GENB is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for GENB.Check RVMD's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, RVMDW has a market cap of 38.3B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while RVMDW trades at $9.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas RVMDW's P/E ratio is -1.11. In terms of profitability, GENB's ROE is -0.27%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, GENB is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for GENB.Check RVMDW's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, ONC has a market cap of 37.5B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while ONC trades at $350.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas ONC's P/E ratio is 61.77. In terms of profitability, GENB's ROE is -0.27%, compared to ONC's ROE of +0.14%. Regarding short-term risk, GENB is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for GENB.Check ONC's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, ALNY has a market cap of 32.9B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while ALNY trades at $239.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas ALNY's P/E ratio is 44.24. In terms of profitability, GENB's ROE is -0.27%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, GENB is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for GENB.Check ALNY's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, ROIV has a market cap of 28.7B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while ROIV trades at $39.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas ROIV's P/E ratio is -37.84. In terms of profitability, GENB's ROE is -0.27%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, GENB is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for GENB.Check ROIV's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, INSM has a market cap of 26B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while INSM trades at $120.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas INSM's P/E ratio is -29.20. In terms of profitability, GENB's ROE is -0.27%, compared to INSM's ROE of -1.11%. Regarding short-term risk, GENB is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for GENB.Check INSM's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, INCY has a market cap of 25.4B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while INCY trades at $125.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas INCY's P/E ratio is 16.84. In terms of profitability, GENB's ROE is -0.27%, compared to INCY's ROE of +0.30%. Regarding short-term risk, GENB is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for GENB.Check INCY's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, BNTX has a market cap of 24.1B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while BNTX trades at $96.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas BNTX's P/E ratio is -12.46. In terms of profitability, GENB's ROE is -0.27%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, GENB is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for GENB.Check BNTX's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, GMAB has a market cap of 21.3B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while GMAB trades at $34.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas GMAB's P/E ratio is 26.18. In terms of profitability, GENB's ROE is -0.27%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, GENB is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for GENB.Check GMAB's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, UTHR has a market cap of 21B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while UTHR trades at $494.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas UTHR's P/E ratio is 17.70. In terms of profitability, GENB's ROE is -0.27%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, GENB is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for GENB.Check UTHR's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas BGNE's P/E ratio is -22.55. In terms of profitability, GENB's ROE is -0.27%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, GENB is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for GENB.Check BGNE's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, GENB's ROE is -0.27%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, GENB is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for GENB.Check DNA-WT's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, JAZZ has a market cap of 15.1B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while JAZZ trades at $240.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas JAZZ's P/E ratio is 8.98. In terms of profitability, GENB's ROE is -0.27%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, GENB is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for GENB.Check JAZZ's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, NBIX has a market cap of 14.7B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while NBIX trades at $146.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas NBIX's P/E ratio is 21.13. In terms of profitability, GENB's ROE is -0.27%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, GENB is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for GENB.Check NBIX's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, ASND has a market cap of 14.7B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while ASND trades at $236.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas ASND's P/E ratio is -97.82. In terms of profitability, GENB's ROE is -0.27%, compared to ASND's ROE of +1.90%. Regarding short-term risk, GENB is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for GENB.Check ASND's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, EXEL has a market cap of 14.7B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while EXEL trades at $58.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas EXEL's P/E ratio is 16.67. In terms of profitability, GENB's ROE is -0.27%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, GENB is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for GENB.Check EXEL's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, SMMT has a market cap of 14.2B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while SMMT trades at $17.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas SMMT's P/E ratio is -15.94. In terms of profitability, GENB's ROE is -0.27%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, GENB is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for GENB.Check SMMT's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, HALO has a market cap of 13.3B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while HALO trades at $112.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas HALO's P/E ratio is 20.98. In terms of profitability, GENB's ROE is -0.27%, compared to HALO's ROE of +1.81%. Regarding short-term risk, GENB is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for GENB.Check HALO's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, BBIO has a market cap of 13B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while BBIO trades at $66.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas BBIO's P/E ratio is -17.81. In terms of profitability, GENB's ROE is -0.27%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, GENB is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for GENB.Check BBIO's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas KRTX's P/E ratio is -28.09. In terms of profitability, GENB's ROE is -0.27%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, GENB is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for GENB.Check KRTX's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, BMRN has a market cap of 12.4B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while BMRN trades at $63.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas BMRN's P/E ratio is 30.74. In terms of profitability, GENB's ROE is -0.27%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, GENB is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for GENB.Check BMRN's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, MDGL has a market cap of 12.3B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while MDGL trades at $531.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas MDGL's P/E ratio is -41.52. In terms of profitability, GENB's ROE is -0.27%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, GENB is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for GENB.Check MDGL's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while TECH trades at $72.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas TECH's P/E ratio is 37.30. In terms of profitability, GENB's ROE is -0.27%, compared to TECH's ROE of +0.09%. Regarding short-term risk, GENB is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for GENB.Check TECH's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas RNAM's P/E ratio is -17.39. In terms of profitability, GENB's ROE is -0.27%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, GENB is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for GENB.Check RNAM's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, AXSM has a market cap of 10.7B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while AXSM trades at $207.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas AXSM's P/E ratio is -54.25. In terms of profitability, GENB's ROE is -0.27%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, GENB is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for GENB.Check AXSM's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, TWST has a market cap of 10.4B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while TWST trades at $166.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas TWST's P/E ratio is -75.22. In terms of profitability, GENB's ROE is -0.27%, compared to TWST's ROE of -0.30%. Regarding short-term risk, GENB is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for GENB.Check TWST's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, KRYS has a market cap of 9.9B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while KRYS trades at $336.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas KRYS's P/E ratio is 42.19. In terms of profitability, GENB's ROE is -0.27%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, GENB is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for GENB.Check KRYS's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, TXG has a market cap of 9.7B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while TXG trades at $76.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas TXG's P/E ratio is -129.83. In terms of profitability, GENB's ROE is -0.27%, compared to TXG's ROE of -0.09%. Regarding short-term risk, GENB is more volatile compared to TXG. This indicates higher risk in terms of short-term price fluctuations for GENB.Check TXG's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, KYMR has a market cap of 9.7B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while KYMR trades at $117.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas KYMR's P/E ratio is -36.80. In terms of profitability, GENB's ROE is -0.27%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, GENB is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for GENB.Check KYMR's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas RXDX's P/E ratio is -56.47. In terms of profitability, GENB's ROE is -0.27%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, GENB is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for GENB.Check RXDX's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, ARWR has a market cap of 9.4B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while ARWR trades at $66.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas ARWR's P/E ratio is -29.55. In terms of profitability, GENB's ROE is -0.27%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, GENB is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for GENB.Check ARWR's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, PTGX has a market cap of 9.2B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while PTGX trades at $143.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas PTGX's P/E ratio is 138.83. In terms of profitability, GENB's ROE is -0.27%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, GENB is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for GENB.Check PTGX's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas NUVL's P/E ratio is -21.79. In terms of profitability, GENB's ROE is -0.27%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, GENB is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for GENB.Check NUVL's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while CRNX trades at $84.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas CRNX's P/E ratio is -16.86. In terms of profitability, GENB's ROE is -0.27%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, GENB is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for GENB.Check CRNX's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, IBRX has a market cap of 8.9B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while IBRX trades at $8.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas IBRX's P/E ratio is -8.74. In terms of profitability, GENB's ROE is -0.27%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, GENB is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for GENB.Check IBRX's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas IMGN's P/E ratio is -111.55. In terms of profitability, GENB's ROE is -0.27%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, GENB is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for GENB.Check IMGN's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, TGTX has a market cap of 8.7B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while TGTX trades at $56.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas TGTX's P/E ratio is 20.61. In terms of profitability, GENB's ROE is -0.27%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, GENB is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for GENB.Check TGTX's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, CYTK has a market cap of 8.6B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while CYTK trades at $68.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas CYTK's P/E ratio is -9.53. In terms of profitability, GENB's ROE is -0.27%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, GENB is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for GENB.Check CYTK's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, CAI has a market cap of 8.5B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while CAI trades at $29.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas CAI's P/E ratio is 84.24. In terms of profitability, GENB's ROE is -0.27%, compared to CAI's ROE of +0.19%. Regarding short-term risk, GENB is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for GENB.Check CAI's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, PCVX has a market cap of 8.4B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while PCVX trades at $58.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas PCVX's P/E ratio is -7.62. In terms of profitability, GENB's ROE is -0.27%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, GENB is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for GENB.Check PCVX's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas BPMC's P/E ratio is -51.58. In terms of profitability, GENB's ROE is -0.27%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, GENB is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for GENB.Check BPMC's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while APGE trades at $135.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas APGE's P/E ratio is -31.19. In terms of profitability, GENB's ROE is -0.27%, compared to APGE's ROE of -0.30%. Regarding short-term risk, GENB is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for GENB.Check APGE's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, PRAX has a market cap of 8.3B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while PRAX trades at $298.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas PRAX's P/E ratio is -23.12. In terms of profitability, GENB's ROE is -0.27%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, GENB is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for GENB.Check PRAX's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas CERE's P/E ratio is -16.47. In terms of profitability, GENB's ROE is -0.27%, compared to CERE's ROE of -0.72%. Regarding short-term risk, GENB is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for GENB.Check CERE's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, SYRE has a market cap of 7.8B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while SYRE trades at $90.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas SYRE's P/E ratio is -46.28. In terms of profitability, GENB's ROE is -0.27%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, GENB is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for GENB.Check SYRE's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, ABVX has a market cap of 7.7B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while ABVX trades at $105.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas ABVX's P/E ratio is -55.06. In terms of profitability, GENB's ROE is -0.27%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, GENB is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for GENB.Check ABVX's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, IMVT has a market cap of 7.6B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while IMVT trades at $36.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas IMVT's P/E ratio is -13.10. In terms of profitability, GENB's ROE is -0.27%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, GENB is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for GENB.Check IMVT's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas MTSR's P/E ratio is -23.58. In terms of profitability, GENB's ROE is -0.27%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, GENB is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for GENB.Check MTSR's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, IONS has a market cap of 7.4B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while IONS trades at $44.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas IONS's P/E ratio is -25.84. In terms of profitability, GENB's ROE is -0.27%, compared to IONS's ROE of -1.11%. Regarding short-term risk, GENB is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for GENB.Check IONS's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, BLTE has a market cap of 6.9B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while BLTE trades at $170.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas BLTE's P/E ratio is -91.42. In terms of profitability, GENB's ROE is -0.27%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, GENB is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for GENB.Check BLTE's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas MRUS's P/E ratio is -17.05. In terms of profitability, GENB's ROE is -0.27%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, GENB is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for GENB.Check MRUS's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas ACLX's P/E ratio is -28.27. In terms of profitability, GENB's ROE is -0.27%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, GENB is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for GENB.Check ACLX's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, RYTM has a market cap of 6.7B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while RYTM trades at $97.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas RYTM's P/E ratio is -31.42. In terms of profitability, GENB's ROE is -0.27%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, GENB is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for GENB.Check RYTM's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, CGON has a market cap of 6.6B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while CGON trades at $74.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas CGON's P/E ratio is -27.74. In terms of profitability, GENB's ROE is -0.27%, compared to CGON's ROE of -0.25%. Regarding short-term risk, GENB is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for GENB.Check CGON's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas RETA's P/E ratio is -66.29. In terms of profitability, GENB's ROE is -0.27%, compared to RETA's ROE of +0.47%. Regarding short-term risk, GENB is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for GENB.Check RETA's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas CNTA's P/E ratio is -22.63. In terms of profitability, GENB's ROE is -0.27%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, GENB is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for GENB.Check CNTA's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, TVTX has a market cap of 5.8B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while TVTX trades at $62.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas TVTX's P/E ratio is -139.47. In terms of profitability, GENB's ROE is -0.27%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, GENB is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for GENB.Check TVTX's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, ORKA has a market cap of 5.7B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while ORKA trades at $94.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas ORKA's P/E ratio is -48.95. In terms of profitability, GENB's ROE is -0.27%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, GENB is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for GENB.Check ORKA's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, LGND has a market cap of 5.7B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while LGND trades at $283.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas LGND's P/E ratio is 31.12. In terms of profitability, GENB's ROE is -0.27%, compared to LGND's ROE of +0.20%. Regarding short-term risk, GENB is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for GENB.Check LGND's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas CDTX's P/E ratio is -19.77. In terms of profitability, GENB's ROE is -0.27%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, GENB is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for GENB.Check CDTX's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, MIRM has a market cap of 5.6B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while MIRM trades at $91.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas MIRM's P/E ratio is -6.31. In terms of profitability, GENB's ROE is -0.27%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, GENB is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for GENB.Check MIRM's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, SRRK has a market cap of 5.6B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while SRRK trades at $46.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas SRRK's P/E ratio is -13.52. In terms of profitability, GENB's ROE is -0.27%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, GENB is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for GENB.Check SRRK's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, GENB's ROE is -0.27%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, GENB is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for GENB.Check ABCM's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas ISEE's P/E ratio is -22.44. In terms of profitability, GENB's ROE is -0.27%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, GENB is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for GENB.Check ISEE's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while PTCT trades at $65.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas PTCT's P/E ratio is -28.06. In terms of profitability, GENB's ROE is -0.27%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, GENB is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for GENB.Check PTCT's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, CRSP has a market cap of 5.5B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while CRSP trades at $56.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas CRSP's P/E ratio is -11.88. In terms of profitability, GENB's ROE is -0.27%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, GENB is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for GENB.Check CRSP's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, DNTH has a market cap of 5.4B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while DNTH trades at $96.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas DNTH's P/E ratio is -23.33. In terms of profitability, GENB's ROE is -0.27%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, GENB is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for GENB.Check DNTH's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, COGT has a market cap of 5.4B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while COGT trades at $31.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas COGT's P/E ratio is -14.93. In terms of profitability, GENB's ROE is -0.27%, compared to COGT's ROE of -0.73%. Regarding short-term risk, GENB is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for GENB.Check COGT's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas APLS's P/E ratio is 38.35. In terms of profitability, GENB's ROE is -0.27%, compared to APLS's ROE of +0.40%. Regarding short-term risk, GENB is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for GENB.Check APLS's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, DFTX has a market cap of 5.2B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while DFTX trades at $38.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas DFTX's P/E ratio is N/A. In terms of profitability, GENB's ROE is -0.27%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, GENB is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for GENB.Check DFTX's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, ERAS has a market cap of 5.1B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while ERAS trades at $14.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas ERAS's P/E ratio is -15.88. In terms of profitability, GENB's ROE is -0.27%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, GENB is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for GENB.Check ERAS's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, EWTX has a market cap of 4.9B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while EWTX trades at $45.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas EWTX's P/E ratio is -24.50. In terms of profitability, GENB's ROE is -0.27%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, GENB is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for GENB.Check EWTX's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, PBLS has a market cap of 4.9B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while PBLS trades at $41.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas PBLS's P/E ratio is -47.42. In terms of profitability, GENB's ROE is -0.27%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, GENB is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for GENB.Check PBLS's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas TERN's P/E ratio is -51.41. In terms of profitability, GENB's ROE is -0.27%, compared to TERN's ROE of -0.20%. Regarding short-term risk, GENB is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for GENB.Check TERN's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, ACAD has a market cap of 4.7B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while ACAD trades at $27.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas ACAD's P/E ratio is 12.29. In terms of profitability, GENB's ROE is -0.27%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, GENB is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for GENB.Check ACAD's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, IOVA has a market cap of 4.6B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while IOVA trades at $10.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas IOVA's P/E ratio is -14.04. In terms of profitability, GENB's ROE is -0.27%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, GENB is more volatile compared to IOVA. This indicates higher risk in terms of short-term price fluctuations for GENB.Check IOVA's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, ADPT has a market cap of 4.6B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while ADPT trades at $28.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas ADPT's P/E ratio is -69.63. In terms of profitability, GENB's ROE is -0.27%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, GENB is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for GENB.Check ADPT's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas FOLD's P/E ratio is -161.00. In terms of profitability, GENB's ROE is -0.27%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, GENB is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for GENB.Check FOLD's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas AKRO's P/E ratio is -14.57. In terms of profitability, GENB's ROE is -0.27%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, GENB is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for GENB.Check AKRO's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas ALPN's P/E ratio is -101.52. In terms of profitability, GENB's ROE is -0.27%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, GENB is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for GENB.Check ALPN's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, MANE has a market cap of 4.5B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while MANE trades at $106.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas MANE's P/E ratio is -33.96. In terms of profitability, GENB's ROE is -0.27%, compared to MANE's ROE of -0.38%. Regarding short-term risk, GENB is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for GENB.Check MANE's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, TLX has a market cap of 4.3B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while TLX trades at $12.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas TLX's P/E ratio is 131.42. In terms of profitability, GENB's ROE is -0.27%, compared to TLX's ROE of +0.07%. Regarding short-term risk, GENB is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for GENB.Check TLX's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas OPT's P/E ratio is -1.52. In terms of profitability, GENB's ROE is -0.27%, compared to OPT's ROE of +1.18%. Regarding short-term risk, GENB is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for GENB.Check OPT's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while PRTC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas PRTC's P/E ratio is -3.78. In terms of profitability, GENB's ROE is -0.27%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, GENB is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for GENB.Check PRTC's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, RLAY has a market cap of 4.1B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while RLAY trades at $18.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas RLAY's P/E ratio is -12.00. In terms of profitability, GENB's ROE is -0.27%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, GENB is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for GENB.Check RLAY's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas MRTX's P/E ratio is -4.82. In terms of profitability, GENB's ROE is -0.27%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, GENB is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for GENB.Check MRTX's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, CELC has a market cap of 3.9B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while CELC trades at $80.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas CELC's P/E ratio is -18.75. In terms of profitability, GENB's ROE is -0.27%, compared to CELC's ROE of -3.51%. Regarding short-term risk, GENB is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for GENB.Check CELC's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, ABCL has a market cap of 3.9B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while ABCL trades at $12.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas ABCL's P/E ratio is -23.39. In terms of profitability, GENB's ROE is -0.27%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, GENB is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for GENB.Check ABCL's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas CPRX's P/E ratio is 12.30. In terms of profitability, GENB's ROE is -0.27%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, GENB is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for GENB.Check CPRX's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, XENE has a market cap of 3.8B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while XENE trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas XENE's P/E ratio is -8.46. In terms of profitability, GENB's ROE is -0.27%, compared to XENE's ROE of -0.44%. Regarding short-term risk, GENB is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for GENB.Check XENE's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, AMLX has a market cap of 3.8B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while AMLX trades at $32.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas AMLX's P/E ratio is -22.63. In terms of profitability, GENB's ROE is -0.27%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, GENB is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for GENB.Check AMLX's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas RYZB's P/E ratio is -57.86. In terms of profitability, GENB's ROE is -0.27%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, GENB is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for GENB.Check RYZB's competition here

Generate Biomedicines, Inc. (NASDAQ: GENB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GENB stands at 2.2B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, GENB is priced at $17.14 on the NASDAQ, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GENB currently has a P/E ratio of -32.96, whereas CBAY's P/E ratio is -32.81. In terms of profitability, GENB's ROE is -0.27%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, GENB is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for GENB.Check CBAY's competition here